Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma
Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma
复制标题
DOI：
10.2217/bmm-2019-0432
复制
发表时间：
2020-10-01
影响因子：
2.2
通讯作者：
Fan, Yaguang
中科院分区：
文献类型：
--
作者：
Sun, Danyang;Zheng, Xiangqian;Fan, Yaguang
背景资料：抗甲状腺球蛋白抗体（TgAb）作为分化型甲状腺癌（DTC）肿瘤标志物的临床价值仍存在争议。材料与方法：我们研究了110例TgAb阳性的DTC患者，他们接受了甲状腺全切除术和I-131治疗。多因素Logistic回归分析预后因素与疾病结局的关系。结果与结论：消融前TgAb水平和首次I-131治疗后6-12个月内TgAb的变化是55岁以下患者疾病结局的危险因素，而甲状腺外扩展是55岁以上患者的危险因素。中位TgAb半衰期为7.7个月，TgAb阳性变为阴性的中位时间为15.8个月。残余消融后第一年内TgAb的动态变化可以预测DTC患者的疾病结局。
Background: The clinical value of antithyroglobulin antibodies (TgAb) as a tumor marker for differentiated thyroid cancer (DTC) is still controversial. Materials & methods: We studied 110 TgAb positive DTC patients who underwent total thyroidectomy and I-131 therapies. Multivariate logistic regression was conducted to analyze the association between prognostic factors and disease outcomes. Results & conclusion: Pre-ablation TgAb levels and the changes of TgAb in 6-12 months after the first I-131 therapy were risk factors for disease outcome in patients younger than 55, while extrathyroid extension was a risk factor in patients older than 55. The median TgAb half-life was 7.7 months and the median time for TgAb positivity to become negative was 15.8 months. The dynamics of TgAb within the first year after remnant ablation could predict disease outcome for DTC patients.